 CV effectiveness tolerability safety study Twenty hyperprolactinemic women median prolactin PRL mU/L mU/L bromocriptine prospective study months new nonergot long-acting dopamine agonist CV Treatment normalization PRL patients daily dose mg drug patients doses mg mg PRL study Menstrual function amenorrheic patients Galactorrhea present patients patients pregnant birth healthy children conclusion CV effective daily dose good tolerability safe valuable alternative dopamine agonist drugs use today